Published in final edited form as:

Cancer Causes Control. 2011 November ; 22(11): 1587–1595. doi:10.1007/s10552-011-9835-3.

Associations of Pregnancy Characteristics with Maternal and Cord Steroid Hormones, Angiogenic Factors, and Insulin-like Growth Factor Axis

Jessica M. Faupel-Badger^{1,2}, Yuping Wang³, S. Ananth Karumanchi⁴, Frank Stanczyk⁵, Michael Pollak⁶, Thomas McElrath⁷, Robert N. Hoover², and Rebecca Troisi²

¹Cancer Prevention Fellowship Program, Center for Cancer Training, National Cancer Institute, Bethesda, MD

²Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

³Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, Shreveport, LA

⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

⁵Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA

⁶Department of Medicine, McGill University, Montreal, Canada

⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Abstract

Background—The objective of this study was to comprehensively profile biological factors in pregnancy that have been postulated to be important components of the *in utero* environment and may also have relevance to later susceptibility to cancer and other chronic diseases.

Methods—Steroid sex hormones, IGFs, and angiogenic factors were measured in maternal and cord serum from term, normotensive pregnancies. Spearman correlations and linear regression estimated relationships among the biological factors and clinical characteristics.

Results—The analytes were generally not correlated between maternal and fetal circulations. However, significant correlations were demonstrated among several analytes within maternal or cord samples. A few analytes were associated with clinical characteristics (e.g., maternal IGF-1 and IGFBP-3 were inversely correlated with offspring birth weight, while maternal leptin and cord testosterone were positively correlated with this characteristic). Maternal androgens were higher in African-Americans than whites and maternal PlGF and soluble fms-like tyrosine kinase-1 (sFlt-1) were higher in male than female offspring.

Conclusions—There were significant correlations among analytes but the patterns differed depending on whether they were measured in the maternal or fetal circulation. The number and magnitude of correlations among analytes, however, should affect the design and interpretation of future studies.

Keywords

African-American; angiogenic factors; IGF; leptin; prolactin

Introduction

Alterations in steroid sex hormones, the insulin-like growth factor axis, and angiogenic proteins have been associated with pregnancy outcomes such as small for gestation age infants (1) and preeclampsia (2–4). For example, prior studies have shown that women who develop preeclampsia have highly elevated circulating levels of the anti-angiogenic proteins soluble fms-like kinase 1 (sFlt1) and soluble endoglin (sEng), both prior to and at clinical diagnosis of the disease (5–13). Androgens (androstenedione and testosterone) also have been shown to be higher in the maternal circulation in women with preeclampsia (2, 4, 14). These endogenous *in utero* exposures also have been associated with later disease susceptibility (15, 16), including cardiovascular health and cancer risk (17) in both the mother and the offspring (18).

Most studies that have examined endogenous *in utero* exposures with the aim of developing biological hypotheses to explain epidemiological associations of pregnancy complications with later risk of cancer have focused exclusively on steroid sex hormones (17, 19, 20) without examining the relationship of the steroid sex hormones to other analytes. Laboratory studies show estrogen can promote expression of vascular endothelial growth factor (VEGF), a potent pro-angiogenic factor, in female endometrium and breast tissue (21–26). Therefore, concentrations of steroid sex hormones may be associated with angiogenic balance. In this report, we sought to examine a comprehensive set of biological factors that have been shown to be important in the maintenance and progression of pregnancy and are also associated with incidence of one or more types of cancer (3, 17, 27–30) to determine if there are discernable patterns of association between these analytes in normal pregnancy. We also hypothesized that maternal and neonatal characteristics will correlate with the levels of these analytes during pregnancy and thereby provide a more expansive profile from which to examine the *in utero* environment and its influence on subsequent risk of cancer or other adult health outcomes.

Methods

Study design and population

Participants included in the present analysis were controls from a case-control study of preeclampsia that was conducted at Louisiana State University Health Sciences Center at Shreveport, LA (31). Controls in the original study were singleton pregnancies that remained normotensive and without proteinuria. Initially only nulliparous women were recruited but this criterion was relaxed later in the study. Exclusion criteria consisted of conceptions via any fertility assistance, chronic hypertension, preexisting or gestational diabetes mellitus, and chronic renal disease. The original study was approved by the Institutional Review Boards (IRB) of Louisiana State University Health Sciences Center and The Eunice Kennedy Shriver National Institute of Child Health and Human Development. The analyses presented here were from anonymized samples and therefore were deemed exempt from IRB review by the NIH Office of Human Subject Research.

Data collection

Medical and demographic information for both mother and offspring was obtained from an in-person interview and medical chart review. A blood sample was collected when the woman was admitted to the labor and delivery unit. After delivery, mixed arterial and

venous umbilical cord serum (referred to as “cord”) samples were collected. Samples were allowed to clot, then centrifuged and serum stored at -80°C .

Laboratory assays

Maternal and cord androstenedione (A4), testosterone (T), estradiol (E2), estriol (E3), progesterone (P), and prolactin (PRL) were measured in the Reproductive Endocrine Research Laboratory, (University of Southern California Keck School of Medicine) by sensitive and specific immunoassays. A4, P, T and E₂ were measured by radioimmunoassays (RIAs) following their extraction with ethyl acetate:hexane (3:2) and separation by Celite column partition chromatography(32–35). E₃ was quantified by RIA after a dual extraction using different concentrations of ethyl acetate in hexane (36). Prolactin was measured by direct chemiluminescent immunoassay on the Immulite analyzer (Siemens Medical Solutions Diagnostics, Malvern, PA). Coefficients of variation (CVs) were 13.3, 6.9, 9.5, 15.4, 10.7, and 4.5% for maternal measures and 14.6, 12.0, 16.3, 8.3, 7.6, and 3.4% for cord measures of A4, T, E₂, E₃, P and PRL, respectively. Placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and soluble endoglin (sEng) were measured in the laboratory of Dr. S. Ananth Karumanchi (Beth Israel Hospital, Harvard Medical School) using the commercially available ELISAs (R&D Systems; Minneapolis, MN). For the maternal measurements the interassay CVs were 5% for sFlt1, 10% for PLGF and 29% for endoglin. The interassay CV for cord sFlt-1 was 15%. PlGF was undetectable in 70% of cord samples; therefore it was not included in the analyses. Cord s-Eng also was excluded from the analyses because of its high CV (42%). IGF-1, IGF-2, IGFBP-3, C-peptide, and leptin were measured in the Pollak Research Laboratory using ELISA methods and reagents from DSL (Webster, TX). The CVs were 9.6, 6.4, 5.7, 8.1, and 4.3% for maternal measures and 9.4, 7.5, 5.7, 8.0, and 3.6% for cord measures of IGF-1, IGF-2, IGFBP-3, C peptide, and leptin, respectively.

Because of limited sera, cord measurements were prioritized based on assay volume requirements to achieve the maximum results from each sample. Thus, the sample sizes vary for each of the cord analytes. For most of the hormones, approximately 70% of the population had both cord and maternal serum measurements: for E₃, IGF-1, and sFlt-1, approximately 58% had both, for IGF-2 52% had both measurements, and for leptin 46% had both, whereas only 25% had both measures for C-peptide. Maternal, prenatal and neonatal characteristics did not differ between pregnancies in which all analytes were measured and those for which levels of one or more analytes were not able to be determined.

Statistics

Because the analyte values tended to be non-normally distributed, Spearman correlations were used to examine the associations among the hormones and proteins 1) for the same analyte between the maternal and cord circulation; 2) among the analytes separately for the maternal and cord circulations; and 3) between maternal and cord measurements and continuous values of maternal and neonatal characteristics. Linear regression models estimated the associations of hormone and protein measures with maternal race or offspring gender after adjustment for gestational age and maternal or neonatal factors significantly associated with the specific hormone or protein concentrations in the univariate analysis reported in Table 6. Analyses were completed with SAS (version 9.0, SAS Institute, Inc., Cary, NC) and statistical significance was defined as two-sided $P < 0.05$.

Results

Demographics of study population and median concentrations of analytes in maternal and cord samples

The maternal, gestational, and neonatal characteristics of the study population are reported in Table 1. A total of 49 women with term pregnancies were included in this study. Of these, 38 were African-American, 3 were Hispanic, and 8 were Caucasian, non-Hispanic. Approximately 65% of the women had vaginal deliveries, while 32% were delivered by caesarean-section. The majority of the women, per design of the parent study, were nulliparous (90%) and, on average, young (mean age 20.5 years) with a self-reported pre-pregnancy body mass index (BMI) of mean 25.9 kg/m². Mean gestational age at delivery was 39 weeks. Maternal and neonatal characteristics did not differ by whether the delivery was vaginal or by caesarean-section (data not shown).

Analyte concentrations in maternal and cord samples

Medians for the sex steroids and proteins measured in both maternal and cord samples are presented in Table 2. For most steroid and protein measures, maternal concentrations were equivalent to or higher than cord concentrations, with the exception of A4, E3, P, and PRL, which were higher in the fetal circulation. The hormone and protein measures were analyzed by method of delivery (vaginal vs. Caesarean) and no significant differences were detected, except for higher cord E2 concentrations associated with vaginal deliveries (data not shown).

Correlation between the same analyte in the maternal and cord circulation

Overall, the only analyte that showed moderate correlation between the maternal and cord circulations was T ($r=0.47$, $p=0.006$). A4, IGF-1, C-peptide, and leptin were weakly correlated between maternal and cord samples; all other hormones and proteins analyzed exhibited no correlation (Table 3).

Patterns of correlation among analytes in the maternal and fetal circulation

The results in Tables 4 and 5 demonstrate multiple, positive correlations between hormones and protein analytes in the maternal and fetal circulations, respectively. When comparing correlations among maternal and cord measures, several consistent patterns were evident. For the most part, the steroid sex hormones were moderately to highly correlated with each other. IGF-1, IGF-2, and IGFBP-3 were also correlated with each other ($r=0.42$ – 0.81) and, in general, with the estrogens.

There also were patterns that differed between the maternal and cord measures. Surprisingly, cord A4 was significantly correlated with all other cord measures ($r=0.38$ – 0.66), except PRL, IGF-2, and C peptide. P and PRL were correlated with members of the IGF axis in maternal samples but not at all in cord samples. Among angiogenic factors, maternal PLGF and sFlt-1 were associated with the maternal sex steroid hormones E2 and P ($r=0.38$ – 0.52) while, in the cord, sFlt-1 correlated with cord sex steroid hormones A4 and T ($r=0.53$ – 0.72).

Associations of pregnancy characteristics with maternal and cord analytes

Univariate analysis demonstrated that only a few maternal or neonatal characteristics were independently associated with any of the hormones or angiogenic factors (Table 6). Birth weight was positively correlated with cord T ($r=0.44$) and inversely correlated with maternal IGF-1 ($r=-0.32$) and IGFBP-3 ($r=-0.31$). Maternal pre-pregnancy weight ($r=0.36$), weight gain ($r=0.39$), and offspring birth weight ($r=0.30$) were correlated with maternal leptin. Maternal age was positively correlated with maternal IGF-2 ($r=0.29$) but inversely

correlated with maternal C-peptide ($r=-0.38$). Placental weight was inversely correlated with maternal IGFBP-3 ($r=-0.42$) and birth length was positively correlated with maternal PIGF ($r=0.29$). When these same associations were examined in linear regression models including gestational age and additional maternal or neonatal characteristics associated with the analyte in univariate analyses, the only associations that remained significant were the inverse associations of maternal IGFBP-3 with placental weight and IGF-1 with birth weight, as well as the positive associations of maternal leptin with maternal weight and weight gain.

Associations with offspring gender also were evaluated in models including gestational age and maternal or neonatal characteristics that were significantly associated with the analyte in univariate analyses. Maternal A4 ($p=0.07$), E3 ($p=0.07$), P ($p=0.01$), sFlt-1 ($p=0.04$), and PIGF ($p=0.03$), as well as cord T ($p=0.03$) were all higher in pregnancies with males than females. For steroid hormones, maternal A4, E3, P, and cord T were approximately 21%, 84%, 68%, and 126% higher, respectively, in pregnancies with male compared to female offspring. Among angiogenic factors, maternal sFlt-1 and PIGF were 46% and 161% higher, respectively, in pregnancies with male compared to female offspring.

Although there was little diversity in the study population with respect to race, we conducted exploratory analyses of potential differences in hormone and protein concentrations between African-Americans and Caucasians, given prior findings that have shown racial differences particularly with steroid hormones. As with offspring gender, analyses including race were adjusted for gestational age and maternal or neonatal characteristics that were significantly associated with the analyte in univariate analysis. In the present data, maternal T ($p=0.04$) and A4 ($p=0.04$) were higher in African-Americans than Caucasians. Cord IGF-1 ($p=0.06$) was higher in Caucasians than in African-Americans. The few Hispanic individuals in this analysis had maternal A4 and T concentrations similar to those in Caucasians but cord IGF-1 levels were more similar to those in African-Americans. There were no differences in angiogenic factor measurements by race/ethnicity in this population.

Discussion

To our knowledge, these data represent the most comprehensive profile of steroid hormones and proteins measured at delivery in matched maternal and cord samples in a largely African-American population. In particular, these are the first data correlating steroid sex hormones with angiogenic factors in pregnancy. There also was little or no correlation between most maternal and cord measures of the same analyte, which has been seen in prior studies (37). When examining maternal or cord measures alone, there was a high degree of correlation among analytes in each sample and some of the correlation patterns among analytes differed depending on whether they are measured in the maternal or cord circulation. These results suggest that cord as well as maternal measurements should be included in studies seeking to characterize pregnancy biomarker concentrations in relation to pregnancy characteristics, as inferences regarding the *in utero* environment will not be accurate if based on maternal samples alone.

Few hormone or protein measures, from either maternal or cord samples, were associated with maternal or neonatal characteristics. Since the majority (>90%) of the women in this study were nulliparous, associations with parity were not evaluated. Notable associations with maternal and neonatal characteristics include those with offspring gender and maternal race. Interestingly, we found that maternal concentrations of several sex steroid hormones and the angiogenic factors PIGF and sFlt-1 were higher in pregnancies with male offspring. Replication of these findings is warranted. Our results regarding higher maternal T and A4 concentrations and lower cord IGF-1 levels in African-American compared to Caucasians

are consistent with prior studies (19, 38, 39). These prior studies have suggested that the variation in pregnancy androgens by race may result in an *in utero* environment that could contribute to later differences in adult cancer susceptibility between African-Americans and Caucasians. Specifically, higher pregnancy androgen levels have been hypothesized to be protective with regard to breast (17) and testicular cancer (19) but a potential risk factor for prostate cancer (19, 38). While we did see differences by race in maternal samples, no variation in cord androgen concentrations was detected. This suggests caution should be used when extrapolating hypotheses based on maternal variation by race to the *in utero* environment of the offspring.

We also observed positive associations of cord T and maternal leptin and inverse associations of maternal IGF-1 and IGFBP-3 with birth weight. Maternal PLGF was associated with birth length. Birth weight is consistently associated with increased breast cancer risk in numerous studies (17, 40–42) and also with childhood leukemia (43). In the meta-analysis by dos Santos Silva, et al., birth length also was independently (of birth weight) associated with breast cancer risk (41). The study included a relatively small sample size which may have limited our ability to detect statistically significant associations. Also, the large number of comparisons could have resulted in chance associations. As in many studies, maternal samples were collected when the woman was admitted to the labor and delivery unit. We cannot exclude that factors associated with delivery, including stress, might influence the associations of maternal analytes with maternal and neonatal characteristics. However, this effect is at best minimal because mode of delivery was not related to mean concentrations of cord or maternal hormones or proteins in our data.

The associations of hormone and/or protein measures with maternal and neonatal characteristics has been central to current hypotheses that suggest the *in utero* milieu may be associated with subsequent cancer risk either directly or indirectly (17, 19, 20, 39, 44). Within this population of healthy, term pregnancies in a predominately African-American population, we saw few associations of maternal and/or neonatal characteristics with the proteins or hormones measured, which may in part be due to the limitations above. However, the significant contributions of this current study include the wide range of analytes measured and demonstration of intercorrelation among many pregnancy hormones and growth factors. These data imply that caution must be applied when evaluating early life/*in utero* exposures and attributing causal associations with chronic disease outcomes to only one measure. These results also highlight the importance of casting a wide net when determining which analytes to measure, although clearly assay costs and volume requirements are a major limitation in epidemiologic studies. One possible approach is to assess a panel of markers to determine a hormonal and/or protein profile in relation to subsequent outcome.

In conclusion, our results demonstrate the need for studies of pregnancy biomarkers to be more inclusive, to evaluate the correlations among analytes, and to include both maternal and cord samples. Larger studies to confirm the associations reported here are needed as are studies aimed at understanding the biological mechanisms (including the hormone and/or protein profile) underlying these associations. Future studies also should be designed to permit analysis of these associations across racial/ethnic subgroups as the *in utero* environment may be part of the explanation for variation in cancer incidence by race/ethnicity.

Acknowledgments

Grant support: This research was supported by federal funds from the National Cancer Institute, National Institutes of Health. Dr. Faupel-Badger's research was supported by the Center for Cancer Training, Cancer Prevention Fellowship Program, NCI.

We would like to thank Lisa Philibert, RN and Kimberly Mandino, RN for patient recruitment and clinical data collection for the study. We also thank Marianne Hyer for her contributions to data verification and analysis and Dr. Jun Zhang for collaborating with us on the parent study.

References

1. Randhawa RS. The insulin-like growth factor system and fetal growth restriction. *Pediatr Endocrinol Rev.* 2008; 6:235–40. [PubMed: 19202510]
2. Troisi R, Potischman N, Roberts JM, Ness R, Crombleholme W, Lykins D, et al. Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. *Int J Epidemiol.* 2003; 32:455–60. [PubMed: 12777436]
3. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. *Annu Rev Pathol.* 5:173–92. [PubMed: 20078220]
4. Acromite MT, Mantzoros CS, Leach RE, Hurwitz J, Dorey LG. Androgens in preeclampsia. *Am J Obstet Gynecol.* 1999; 180:60–3. [PubMed: 9914579]
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med.* 2006; 355:992–1005. [PubMed: 16957146]
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med.* 2004; 350:672–83. [PubMed: 14764923]
7. Levine RJ, Qian C, Maynard SE, Yu KF, Epstein FH, Karumanchi SA. Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. *Am J Obstet Gynecol.* 2006; 194:1034–41. [PubMed: 16580293]
8. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest.* 2003; 111:649–58. [PubMed: 12618519]
9. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. *Hypertension.* 2007; 50:137–42. [PubMed: 17515455]
10. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. *J Matern Fetal Neonatal Med.* 2008; 21:9–23. [PubMed: 18175241]
11. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. *Eur J Obstet Gynecol Reprod Biol.* 2005; 122:33–9. [PubMed: 15935542]
12. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. *J Clin Endocrinol Metab.* 2004; 89:770–5. [PubMed: 14764795]
13. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med.* 2006; 12:642–9. [PubMed: 16751767]
14. Salamalekis E, Bakas P, Vitoratos N, Eleftheriadis M, Creatas G. Androgen levels in the third trimester of pregnancy in patients with preeclampsia. *Eur J Obstet Gynecol Reprod Biol.* 2006; 126:16–9. [PubMed: 16139944]
15. Barker DJ. Fetal origins of coronary heart disease. *BMJ.* 1995; 311:171–4. [PubMed: 7613432]
16. Barker DJ. The origins of the developmental origins theory. *J Intern Med.* 2007; 261:412–7. [PubMed: 17444880]
17. Troisi R, Potischman N, Hoover RN. Exploring the underlying hormonal mechanisms of prenatal risk factors for breast cancer: a review and commentary. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1700–12. [PubMed: 17855685]
18. Ekblom A. Growing evidence that several human cancers may originate in utero. *Semin Cancer Biol.* 1998; 8:237–44. [PubMed: 9870030]

19. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. *Br J Cancer*. 1988; 57:216–8. [PubMed: 3358915]
20. Trichopoulos D. Hypothesis: does breast cancer originate in utero? *Lancet*. 1990; 335:939–40. [PubMed: 1970028]
21. Albrecht ED, Babischkin JS, Lidor Y, Anderson LD, Udoff LC, Pepe GJ. Effect of estrogen on angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells. *Hum Reprod*. 2003; 18:2039–47. [PubMed: 14507818]
22. Albrecht ED, Pepe GJ. Steroid hormone regulation of angiogenesis in the primate endometrium. *Front Biosci*. 2003; 8:d416–29. [PubMed: 12456304]
23. Dabrosin C. Sex steroid regulation of angiogenesis in breast tissue. *Angiogenesis*. 2005; 8:127–36. [PubMed: 16211362]
24. Hyder SM, Chiappetta C, Stancel GM. Induction of the angiogenic factor VEGF in the uterus by the antiprogesterin onapristone. *Cancer Lett*. 2000; 156:101–7. [PubMed: 10840165]
25. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. *Cancer Res*. 2000; 60:3183–90. [PubMed: 10866309]
26. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. *Trends Endocrinol Metab*. 21:529–36. [PubMed: 20646932]
27. Gingery A, Bahe EL, Gilbert JS. Placental ischemia and breast cancer risk after preeclampsia: tying the knot. *Expert Rev Anticancer Ther*. 2009; 9:671–81. [PubMed: 19445583]
28. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst*. 2002; 94:606–16. [PubMed: 11959894]
29. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. *Expert Opin Ther Targets*. 14:443–51. [PubMed: 20230196]
30. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. *Cytokine Growth Factor Rev*. 2009; 20:193–201. [PubMed: 19520599]
31. Zhang J, Masciocchi M, Lewis D, Sun W, Liu A, Wang Y. Placental anti-oxidant gene polymorphisms, enzyme activity, and oxidative stress in preeclampsia. *Placenta*. 2008; 29:439–43. [PubMed: 18387669]
32. Goebelsmann, AE.; Bernstein, GS.; Gale, JA.; Kletzky, OA.; Nakamura, RM.; Coulson, AH., et al., editors. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. New York: Academic Press; 1979.
33. Goebelsmann U, Horton R, Mestman JH, Arce JJ, Nagata Y, Nakamura RM, et al. Male pseudohermaphroditism due to testicular 17 -hydroxysteroid dehydrogenase deficiency. *J Clin Endocrinol Metab*. 1973; 36:867–79. [PubMed: 4349047]
34. Probst-Hensch NM, Ingles SA, Diep AT, Haile RW, Stanczyk FZ, Kolonel LN, et al. Aromatase and breast cancer susceptibility. *Endocr Relat Cancer*. 1999; 6:165–73. [PubMed: 10731105]
35. Scott JZ, Stanczyk FZ, Goebelsmann U, Mishell DR Jr. A double-antibody radioimmunoassay for serum progesterone using progesterone-3-(O-carboxymethyl) oximino-[125I]-iodo-histamine as radioligand. *Steroids*. 1978; 31:393–405. [PubMed: 307289]
36. Katagiri H, Stanczyk FZ, Goebelsmann U. Estriol in pregnancy. III. Development, comparison and use of specific antisera for rapid radioimmunoassay of unconjugated estriol in pregnancy plasma. *Steroids*. 1974; 24:225–38. [PubMed: 4278765]
37. Troisi R, Potischman N, Roberts JM, Harger G, Markovic N, Cole B, et al. Correlation of serum hormone concentrations in maternal and umbilical cord samples. *Cancer Epidemiol Biomarkers Prev*. 2003; 12:452–6. [PubMed: 12750241]
38. Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegué D, Akereyeni F, Bradwin G, et al. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. *Cancer Epidemiol Biomarkers Prev*. 2009; 18:1484–91. [PubMed: 19423525]
39. Potischman N, Troisi R, Thadhani R, Hoover RN, Dodd K, Davis WW, et al. Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2005; 14:1514–20. [PubMed: 15941965]

40. Park SK, Kang D, McGlynn KA, Garcia-Closas M, Kim Y, Yoo KY, et al. Intrauterine environments and breast cancer risk: meta-analysis and systematic review. *Breast Cancer Res.* 2008; 10:R8. [PubMed: 18205956]
41. Silva Idos S, De Stavola B, McCormack V. Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. *PLoS Med.* 2008; 5:e193. [PubMed: 18828667]
42. Xu X, Dailey AB, Peoples-Sheps M, Talbott EO, Li N, Roth J. Birth weight as a risk factor for breast cancer: a meta-analysis of 18 epidemiological studies. *J Womens Health (Larchmt).* 2009; 18:1169–78. [PubMed: 19630536]
43. Caughey RW, Michels KB. Birth weight and childhood leukemia: a meta-analysis and review of the current evidence. *Int J Cancer.* 2009; 124:2658–70. [PubMed: 19173295]
44. Troisi R, Lagiou P, Trichopoulos D, Xu B, Chie L, Stanczyk FZ, et al. Cord serum estrogens, androgens, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 in Chinese and U.S. Caucasian neonates. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:224–31. [PubMed: 18199728]

Table 1

Descriptive characteristics of the study sample

Characteristic	N	Mean	Range	SD
Gestational age (weeks)	49	39.0	34.0–41.3	1.5
Birth weight (g)	49	3209	2385–4110	445.2
Birth length (cm)	48	46.4	20.0–54.6	5.8
Head circumference (cm)	48	33.5	30.5–37.0	1.3
Maternal age (years)	46	20.5	15–32	3.4
Maternal pre-pregnancy weight (lbs)	46	151	95–250	43.7
Maternal height (in)	49	64.0	59–70	2.6
Maternal pre-pregnancy Body Mass Index (wt(kg)/ht (m) ²)	45	25.9	16.8–43.1	6.9
Maternal weight gain (lbs)	45	34	–18 – +114	25.6

Table 2

Median concentrations of hormones and proteins in maternal and mixed cord serum samples from uncomplicated pregnancies

Analyte	N	Median	Range	SD
Androstenedione (ng/ml)				
Maternal	48	5.3	1.9–19.8	3.4
Cord	34	8.0	3.3–92.3	15.0
Testosterone (ng/dl)				
Maternal	48	230	73.2–835	184
Cord	34	37.6	9.5–631	125
Estradiol (ng/ml)				
Maternal	48	25.4	0.2–65.8	19.0
Cord	34	16.6	1.2–182	40.3
Estriol (ng/ml)				
Maternal	48	14.7	0.5–31.5	9.1
Cord	29	276	0.2–831	203
Progesterone (ng/ml)				
Maternal	48	145	17–308	74
Cord	32	1706	202–4007	934
PRL (ng/ml)				
Maternal	48	144	44.3–338	67.8
Cord	34	337	48.6–904	191
IGF1 (ng/ml)				
Maternal	47	161	22–399	86
Cord	28	67	41–311	52
IGF2 (ng/ml)				
Maternal	48	1748	620–3039	479
Cord	25	795	459–1356	257

Analyte	N	Median	Range	SD
IGFBP3 (ng/ml)				
Maternal	48	5.2	2.4–8.2	1.4
Cord	34	1.5	0.7–5.1	0.9
C-peptide (ng/ml)				
Maternal	35	0.7	0.3–2.6	0.6
Cord	12	0.5	0.3–1.0	0.2
Leptin (ng/ml)				
Maternal	46	32.4	3.8–109	22.6
Cord	22	11.6	2.0–76	17.7
sFlt1 (pg/ml)				
Maternal	48	7478	1620–20348	5050
Cord	28	1100	20–366923	85627
PLGF (pg/ml)				
Maternal	48	113	1–688	141
Endoglin (ng/ml)				
Maternal	48	10.8	2.0–33.6	8.6

Table 3

Spearman correlations of maternal and mixed cord serum hormone and protein concentrations in uncomplicated pregnancies.

Analyte	N	r_s	P value
Androstenedione	33	0.30	0.09
Testosterone	33	0.47	0.006
Estradiol	33	-0.11	0.55
Estriol	28	-0.06	0.76
Progesterone	31	-0.05	0.79
Prolactin	33	0.006	0.97
Insulin-like growth factor-1	27	0.21	0.28
Insulin-like growth factor-2	24	-0.07	0.74
IGF binding protein 3	33	0.07	0.68
C-peptide	10	0.30	0.40
Leptin	21	0.34	0.13
sFlt-1	27	-0.04	0.74

Table 4
Spearman correlations among hormone and protein concentrations in maternal serum from uncomplicated pregnancies

Analyte	A4	T	E2	E3	Prog	PRL	IGF1	IGF2	IGFBP3	C-pep	Leptin	sFlt-1	PlGF	Endog
A4	-----													
Testosterone	0.81*	-----												
Estradiol	0.35*	0.12	-----											
Estriol	0.27	0.07	0.82*	-----										
Progesterone	0.23	-0.06	0.73*	0.73*	-----									
Prolactin	0.11	0.01	0.18	0.24	0.07	-----								
IGF1	0.01	-0.12	0.31*	0.36*	0.39*	0.50*	-----							
IGF2	-0.12	-0.09	0.14	0.15	0.18	0.33*	0.44*	-----						
IGFBP3	-0.02	-0.07	0.25	0.23	0.38*	0.40*	0.77*	0.81*	-----					
C-peptide	0.09	0.01	-0.04	0.13	-0.09	-0.03	0.01	-0.21	-0.19	-----				
Leptin	-0.004	-0.03	0.19	0.24	0.19	0.07	0.07	0.05	-0.08	-0.17	-----			
sFlt1	0.22	0.10	0.38*	0.27	0.50*	0.03	0.29*	0.14	0.26	0.22	0.05	-----		
PlGF	0.01	-0.12	0.46*	0.53*	0.52*	0.03	0.09	0.17	0.22	-0.05	0.21	-0.03	-----	
Endoglin	0.18	0.10	0.01	-0.04	-0.003	0.26	0.17	-0.01	-0.01	0.20	0.16	0.40*	-0.17	-----

* P<0.05

Table 5
Spearman correlations among hormone and protein concentrations in mixed cord serum from uncomplicated pregnancies

Analyte	A4	T	E2	E3	Prog	PRL	IGF1	IGF2	IGFBP3	C-pep	Leptin	sFlt-1
A4	-----											
Testosterone	0.66*	-----										
Estradiol	0.46*	0.22	-----									
Estriol	0.47*	0.31	0.33	-----								
Progesterone	0.53*	0.06	0.47*	0.50*	-----							
Prolactin	0.009	-0.26	0.08	0.18	0.28	-----						
IGF1	0.38*	0.32	0.18	0.39*	0.03	0.09	-----					
IGF2	0.24	0.40*	0.005	0.34	0.06	0.23	0.42*	-----				
IGFBP3	0.44*	0.51*	0.12	0.33	0.10	0.03	0.65*	0.52*	-----			
C-peptide	-0.15	0.10	-0.41	-0.13	-0.75*	-0.50	-0.06	-0.62*	0.05	-----		
Leptin	0.56*	0.50*	0.07	0.24	0.20	-0.01	0.62*	-0.02	0.48*	0.17	-----	
sFlt1	0.53*	0.72*	0.14	0.39	0.17	-0.13	0.20	0.63*	0.35	-0.45	0.29	-----

* P<0.05

Spearman correlations of maternal and mixed cord serum hormone and protein concentrations with maternal, neonatal, and gestational characteristics in uncomplicated pregnancies

Table 6

Analyte	Gestational Age	Birth Weight	Birth Length	Head Circ	Maternal Age	Maternal Pre-pregnancy Weight	Maternal WeightGain	Maternal Height	Placental Weight
Androstenedione	Maternal	0.16	0.17	0.05	0.11	-0.03	0.16	0.04	0.17
	Cord	0.11	0.16	0.04	0.17	0.005	-0.15	-0.02	0.05
Testosterone	Maternal	0.22	0.20	0.07	0.10	0.00005	0.21	0.18	0.08
	Cord	0.21	0.44*	0.24	0.32	0.07	0.01	0.01	0.18
Estradiol	Maternal	0.01	0.06	0.13	0.26	0.01	0.17	-0.04	-0.11
	Cord	-0.16	0.01	0.01	-0.001	0.04	0.10	0.11	0.13
Estriol	Maternal	-0.18	0.007	0.06	0.15	0.05	0.22	-0.05	0.05
	Cord	0.14	0.26	-0.31	0.02	0.24	-0.30	-0.10	-0.11
Progesterone	Maternal	-0.11	0.02	0.13	0.15	-0.05	-0.08	-0.23	-0.12
	Cord	-0.04	-0.10	-0.12	-0.11	0.09	-0.24	0.07	-0.24
Prolactin	Maternal	0.04	-0.15	0.06	-0.11	0.10	0.09	0.16	-0.14
	Cord	0.31	-0.16	-0.12	-0.25	-0.25?	-0.34*	-0.42*	-0.33
IGF1	Maternal	-0.25	-0.32*	-0.05	-0.19	-0.17	-0.03	0.14	-0.27
	Cord	-0.18	0.13	0.03	0.07	0.06	-0.06	0.20	0.12
IGF2	Maternal	-0.11	-0.12	0.08	-0.02	0.29*	0.10	0.04	-0.18
	Cord	0.27	0.21	-0.11	0.04	0.22	-0.01	-0.02	0.26

Analyte	Gestational Age	Birth Weight	Birth Length	Head Circ	Maternal Age	Maternal Pre-pregnancy Weight	Maternal WeightGain	Maternal Height	Placental Weight
IGFBP3	Maternal	−0.31 [*]	0.006	−0.23	0.02	−0.03	−0.14	−0.02	−0.42 [*]
	Cord	0.26	−0.08	0.12	0.13	0.07	0.03	0.01	0.06
C-peptide	Maternal	−0.07	−0.24	−0.02	−0.38 [*]	−0.24	0.05	0.07	0.28
	Cord	−0.01	0.12	0.02	0.38	0.34	−0.19	0.21	0.07
Leptin	Maternal	−0.09	0.27	0.21	0.19	0.36 [*]	0.39 [*]	0.17	0.15
	Cord	−0.02	0.30	0.29	−0.30	−0.28	0.25	0.02	0.21
sFlt1	Maternal	0.01	0.05	0.12	−0.08	−0.09	0.23	−0.09	−0.27
	Cord	0.37	0.07	0.11	0.12	−0.04	−0.01	−0.19	0.07
PlGF	Maternal	−0.07	0.0004	0.09	0.10	0.03	0.02	−0.17	0.05
	Cord	0.0004	0.25 [*]	0.09	0.10	0.03	0.02	−0.17	0.05
Enodglin	Maternal	−0.03	0.06	−0.10	0.05	0.05	0.14	0.19	0.11
	Cord	0.06	0.20	−0.10	0.05	0.05	0.14	0.19	0.11

* P<0.05